{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:05:04Z","timestamp":1787990704520,"version":"build-2784847793"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T00:00:00Z","timestamp":1165449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Background:\u2002<\/jats:bold> ABO\u2010incompatible living\u2010donor liver transplantation (LDLT) requires a reduction of the anti\u2010ABO antibody titer to &lt;16 before transplantation, which is usually achieved by pre\u2010operative plasma exchange (PE) or double\u2010filtration plasmapheresis. ABO\u2010incompatible transplantations have been performed after a splenectomy with heavy drug immunosupression plus B\u2010cell\u2010specific drugs. Here, we evaluated a pre\u2010transplantation infusion protocol with an anti\u2010CD20 monoclonal antibody (rituximab) for ABO\u2010incompatible LDLT.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Between March 2002 and December 2005, 73 adult patients underwent LDLT without retransplantation in our institution. Among these cases, 57 were ABO\u2010identical, 11 were ABO\u2010compatible and five were ABO\u2010incompatible. The rituximab infusion protocol consisted of a weekly infusion of rituximab (375\u2003mg\/m<jats:sup>2<\/jats:sup>) for three wk, which was administered to three of the five ABO\u2010incompatible LDLT patients. All three patients underwent a pre\u2010operative PE, as well as a splenectomy during the operation. A triple immunosuppression protocol of tacrolimus, low\u2010dose steroids and mycophenolate mofetil (1500\u2003mg\/d) was administered post\u2010operatively. In addition, the patients received a continuous intra\u2010arterial infusion of prostaglandin E<jats:sub>1<\/jats:sub> and methylprednisolone, and a continuous intra\u2010portal infusion of a protease inhibitor for three and two wk after transplantation, respectively.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> After the first rituximab infusion, the peripheral blood CD19<jats:sup>+<\/jats:sup> B cell count rapidly decreased to &lt;1%. All three patients treated with rituximab subsequently received an ABO\u2010incompatible LDLT, with donor\/recipient blood groups of B\/O, A<jats:sub>1<\/jats:sub>\/B and A<jats:sub>1<\/jats:sub>\/O. In two cases, the ABO\u2010antibody level transiently increased post\u2010operatively, then decreased and remained low. Rituximab infusion therapy did not develop any direct side effect except for mild allergic reaction to the first infusion, but post\u2010operatively all three patients suffered a cytomegalovirus and were successfully treated with ganciclovir, and one patient had a MRSA\u2010positive intra\u2010abdominal abscess. Two patients are currently alive at 20 and 18\u2003months respectively, and show normal graft\u2010liver function. But one patient died of sepsis because of intra\u2010abdominal abscess.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Although the protocol of rituximab administration is a conventional and safe regimen with no major side effects, the development of a new protocol is needed for prevention of the infection with bone suppression.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2006.00572.x","type":"journal-article","created":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T09:23:28Z","timestamp":1165483408000},"page":"24-31","source":"Crossref","is-referenced-by-count":36,"title":["Experiences and problems pre\u2010operative anti\u2010CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO\u2010incompatible living\u2010donor liver transplantation"],"prefix":"10.1111","volume":"21","author":[{"given":"Masanobu","family":"Usui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Isaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Uemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.1993.tb00673.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199409150-00004"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200206270-00021"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200211150-00001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000078622.43689.D4"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200203270-00013"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000149337.40911.E4"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00304.x"},{"key":"e_1_2_5_10_2","first-page":"634","article-title":"Liver transplantation in Japan \u2013 Registry by the Japanese Liver Transplantation Society","volume":"39","author":"The Japanese Liver Transplantation Society","year":"2005","journal-title":"Jpn J Transplantation"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050016"},{"key":"e_1_2_5_12_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffiier B","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200207150-00014"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00180.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(02)03824-9"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.2003.00024.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.4.1242"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2003.tb00286.x"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2006.00572.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2006.00572.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T21:27:12Z","timestamp":1696886832000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2006.00572.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1399-0012.2006.00572.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2006.00572.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}